Concepedia

Andrew Thomason

AT

Statistics

Publications

7

Citations

789

H-Index

7

Active since

1998

Affiliations

AstraZeneca (United Kingdom)(Current)

Virginia Commonwealth University

Andrew Thomason is an author at AstraZeneca (United Kingdom) specializing in medicine, radiation therapy, and tumor biology.

ORCID

Top concepts

Publications per year

1998–2019

7

Publications

7

Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.

Catherine L. Farrell, J. V. Bready, Karen Rex et al. · PubMed · 1998 · 362 citations

, , +19

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2019 · 155 citations · Full text

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>

Sarah A. Loddick, Sarah J. Ross, Andrew Thomason et al. · Molecular Cancer Therapeutics · 2013 · 77 citations · Full text

Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase

Sébastien L. Degorce, Bernard Barlaam, Elaine Cadogan et al. · Journal of Medicinal Chemistry · 2016 · 73 citations · Full text

, , +18

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Jeremy Karlin, Jasmine Allen, Syed Farhan Ahmad et al. · Molecular Cancer Therapeutics · 2018 · 61 citations · Full text

1–5 of 7